Iron isomaltoside 1000 - Pharmacosmos

Drug Profile

Iron isomaltoside 1000 - Pharmacosmos

Alternative Names: Diafer; Iron oligosaccharide; Isofer; Jilazo; Monofar; Monofer; Monover; NS 32

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacosmos
  • Developer Cosmopharm; Nippon Shinyaku; Pharmacosmos
  • Class Antianaemics; Disaccharides; Ferric compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Metabolic disorders

Most Recent Events

  • 11 Sep 2017 Pharmacosmos initiates enrolment in a phase III trial for Iron deficiency anaemia in Denmark (EudraCT2017-002452-87)
  • 08 Aug 2017 Pharmacosmos plans the phase III IDA-04 trial for Iron deficiency anaemia(NCT03238911)
  • 04 Aug 2017 Pharmacosmos plans the phase III IDA-05 trial for Iron deficiency anaemia (NCT03237065)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top